Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?

Peptide–drug conjugates (PDCs) are the next generation of targeted therapeutics drug after antibody–drug conjugates (ADCs), with the core benefits of enhanced cellular permeability and improved drug selectivity. Two drugs are now approved for market by US Food and Drug Administration (FDA), and in t...

Full description

Saved in:
Bibliographic Details
Published in:Acta pharmaceutica Sinica. B 2023-02, Vol.13 (2), p.498-516
Main Authors: Fu, Chen, Yu, Lifeng, Miao, Yuxi, Liu, Xinli, Yu, Zhaojin, Wei, Minjie
Format: Article
Language:English
Subjects:
Drug
Linker
Peptide
Permeability
Review
Stability
Targeted therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Peptide–drug conjugates (PDCs) are the next generation of targeted therapeutics drug after antibody–drug conjugates (ADCs), with the core benefits of enhanced cellular permeability and improved drug selectivity. Two drugs are now approved for market by US Food and Drug Administration (FDA), and in the last two years, the pharmaceutical companies have been developing PDCs as targeted therapeutic candidates for cancer, coronavirus disease 2019 (COVID-19), metabolic diseases, and so on. The therapeutic benefits of PDCs are significant, but poor stability, low bioactivity, long research and development time, and slow clinical development process as therapeutic agents of PDC, how can we design PDCs more effectively and what is the future direction of PDCs? This review summarises the components and functions of PDCs for therapeutic, from drug target screening and PDC design improvement strategies to clinical applications to improve the permeability, targeting, and stability of the various components of PDCs. This holds great promise for the future of PDCs, such as bicyclic peptide‒toxin coupling or supramolecular nanostructures for peptide-conjugated drugs. The mode of drug delivery is determined according to the PDC design and current clinical trials are summarised. The way is shown for future PDC development. This review summarizes the function of each component of the peptide–drug conjugate (PDC) and design factors and the desired mechanism of action. [Display omitted]
ISSN:2211-3835
2211-3843
DOI:10.1016/j.apsb.2022.07.020